Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers.

AI/ML

Biotechnology

Health Care

Software

Oncoustics AI

Beth Rogozinski

Miriam Naim Ibrahim

Raúl Blázquez García

Shahid Rashid

Ahmed E.

The Engineering and Development team at Oncoustics AI is responsible for creating sophisticated AI algorithms and software solutions that analyze raw ultrasound signals to differentiate between healthy and diseased tissues. This team, comprising machine learning engineers, software developers, and scientists, works collaboratively to develop, refine, and implement non-invasive diagnostic tools aimed at addressing high unmet clinical needs in diseases such as liver fibrosis, among others. Their efforts are focused on ensuring that these advanced diagnostic solutions align with existing medical standards and achieve regulatory approval.

Engineering and Development

Clinical and Data Operations

Engineering and Development

About

Team members

Other teams at Oncoustics AI

Clinical and Data Operations